N-Methyl-D-Aspartate Receptor Antagonist Effects on Prefrontal Cortical Connectivity Better Model Early Than Chronic Schizophrenia
暂无分享,去创建一个
Michael W. Cole | Alan Anticevic | John H. Krystal | Philip R. Corlett | P. Corlett | J. Krystal | A. Anticevic | A. Savic | Aleksandar Savic
[1] T. Insel. Rethinking schizophrenia , 2010, Nature.
[2] L. Fabre,et al. Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. , 1999, The American journal of psychiatry.
[3] Alan D. Lopez,et al. The global burden of disease: a comprehensive assessment of mortality and disability from diseases injuries and risk factors in 1990 and projected to 2020. , 1996 .
[4] M. Laruelle,et al. Increased dopamine transmission in schizophrenia: relationship to illness phases , 1999, Biological Psychiatry.
[5] M. Bergström,et al. In vivo demonstration of enzyme activity in endocrine pancreatic tumors: decarboxylation of carbon-11-DOPA to carbon-11-dopamine. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[6] R. Baldessarini,et al. Schizophrenia, 3rd ed , 2012 .
[7] M. Chafee,et al. Translational and developmental perspective on N-methyl-D-aspartate synaptic deficits in schizophrenia , 2006, Development and Psychopathology.
[8] Gustavo Deco,et al. computational neuroscience approach to schizophrenia and its onset , 2011 .
[9] J. Overall,et al. The Brief Psychiatric Rating Scale , 1962 .
[10] Harry B. G. Ganzeboom,et al. Internationally Comparable Measures of Occupational Status for the 1988 International Standard Classification of Occupations , 1996 .
[11] A. Malhotra,et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. , 1999, The American journal of psychiatry.
[12] Thomas R. Insel,et al. Endophenotypes: Bridging Genomic Complexity and Disorder Heterogeneity , 2009, Biological Psychiatry.
[13] Xiao-Jing Wang,et al. NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia , 2012, Proceedings of the National Academy of Sciences.
[14] Tyrone D. Cannon,et al. Cortex mapping reveals regionally specific patterns of genetic and disease-specific gray-matter deficits in twins discordant for schizophrenia , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[15] C. Carter,et al. Impairments in frontal cortical gamma synchrony and cognitive control in schizophrenia. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[16] B. Moghaddam,et al. NMDA Receptor Hypofunction Produces Opposite Effects on Prefrontal Cortex Interneurons and Pyramidal Neurons , 2007, The Journal of Neuroscience.
[17] H. Holcomb,et al. Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task. , 2001, The American journal of psychiatry.
[18] A. Malhotra,et al. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. , 1997, The American journal of psychiatry.
[19] B. Carroll,et al. Psychopathology and the brain , 1991 .
[20] A. Belger,et al. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development , 2003, Psychopharmacology.
[21] S. Woods,et al. The schizophrenia prodrome: a developmentally informed review and update for psychopharmacologic treatment. , 2006, Child and adolescent psychiatric clinics of North America.
[22] G. McCarthy,et al. The Impact of NMDA Receptor Blockade on Human Working Memory-Related Prefrontal Function and Connectivity , 2013, Neuropsychopharmacology.
[23] J. Krystal,et al. Contributions of Glutamate and GABA Systems to the Neurobiology and Treatment of Schizophrenia , 2011 .
[24] Peter R Luijten,et al. Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies. , 2013, Schizophrenia bulletin.
[25] N. Andreasen,et al. Antipsychotic Dose Equivalents and Dose-Years: A Standardized Method for Comparing Exposure to Different Drugs , 2010, Biological Psychiatry.
[26] P. Fletcher,et al. Time, action and psychosis: Using subjective time to investigate the effects of ketamine on sense of agency , 2013, Neuropsychologia.
[27] H. Meltzer,et al. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. , 2004, The American journal of psychiatry.
[28] F. Vollenweider,et al. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG) , 1997, European Neuropsychopharmacology.
[29] L. Garey. When cortical development goes wrong: schizophrenia as a neurodevelopmental disease of microcircuits , 2010, Journal of anatomy.
[30] Walter Schneider,et al. Identifying the brain's most globally connected regions , 2010, NeuroImage.
[31] S. Mosolov,et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial , 2007, Nature Medicine.
[32] M. Kubicki,et al. Review of functional and anatomical brain connectivity findings in schizophrenia , 2013, Current opinion in psychiatry.
[33] C. Carter,et al. Impairments in frontal cortical γ synchrony and cognitive control in schizophrenia , 2006, Proceedings of the National Academy of Sciences.
[34] Jacob Cohen,et al. A power primer. , 1992, Psychological bulletin.
[35] D Hell,et al. Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. , 2000, Journal of psychiatric research.
[36] N. Ryan,et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.
[37] S. Haber,et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. , 2010, Archives of general psychiatry.
[38] Michael W. Cole,et al. Characterizing thalamo-cortical disturbances in schizophrenia and bipolar illness. , 2014, Cerebral cortex.
[39] M. Laruelle,et al. Neurobiology of dopamine in schizophrenia. , 2007, International review of neurobiology.
[40] D R Medoff,et al. Ketamine activates psychosis and alters limbic blood flow in schizophrenia , 1995, Neuroreport.
[41] Beatriz Paniagua,et al. Imaging Patients with Psychosis and a Mouse Model Establishes a Spreading Pattern of Hippocampal Dysfunction and Implicates Glutamate as a Driver , 2013, Neuron.
[42] Michael W. Cole,et al. The role of default network deactivation in cognition and disease , 2012, Trends in Cognitive Sciences.
[43] D. Cyril D’Souza,et al. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects , 2005, Psychopharmacology.
[44] Deanna M. Barch,et al. Cognition in schizophrenia: core psychological and neural mechanisms , 2012, Trends in Cognitive Sciences.
[45] E. Bora,et al. Neuroanatomical abnormalities in schizophrenia: A multimodal voxelwise meta-analysis and meta-regression analysis , 2011, Schizophrenia Research.
[46] Garry D. Honey,et al. Schizophrenia, ketamine and cannabis: evidence of overlapping memory deficits , 2006, Trends in Cognitive Sciences.
[47] Jong H. Yoon,et al. Association of dorsolateral prefrontal cortex dysfunction with disrupted coordinated brain activity in schizophrenia: relationship with impaired cognition, behavioral disorganization, and global function. , 2008, The American journal of psychiatry.
[48] Michael W. Cole,et al. Altered global brain signal in schizophrenia , 2014, Proceedings of the National Academy of Sciences.
[49] A. Dickinson,et al. Frontal responses during learning predict vulnerability to the psychotogenic effects of ketamine: linking cognition, brain activity, and psychosis. , 2006, Archives of general psychiatry.
[50] J. Morrison,et al. NMDA Receptors Subserve Persistent Neuronal Firing during Working Memory in Dorsolateral Prefrontal Cortex , 2013, Neuron.
[51] Jared X. Van Snellenberg,et al. Functional neuroimaging of working memory in schizophrenia: task performance as a moderating variable. , 2006, Neuropsychology.
[52] Brian A. Nosek,et al. Power failure: why small sample size undermines the reliability of neuroscience , 2013, Nature Reviews Neuroscience.
[53] Anderson M. Winkler,et al. Global Prefrontal and Fronto-Amygdala Dysconnectivity in Bipolar I Disorder with Psychosis History , 2013, Biological Psychiatry.
[54] Michael W. Cole,et al. Variable Global Dysconnectivity and Individual Differences in Schizophrenia , 2011, Biological Psychiatry.
[55] J. Krystal,et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.
[56] Sheng Zhang,et al. Global Resting-State Functional Magnetic Resonance Imaging Analysis Identifies Frontal Cortex, Striatal, and Cerebellar Dysconnectivity in Obsessive-Compulsive Disorder , 2014, Biological Psychiatry.
[57] S. Kapur,et al. From dopamine to salience to psychosis—linking biology, pharmacology and phenomenology of psychosis , 2005, Schizophrenia Research.
[58] G. McCarthy,et al. Relationship of Resting Brain Hyperconnectivity and Schizophrenia-like Symptoms Produced by the NMDA receptor Antagonist Ketamine in Humans , 2012, Molecular Psychiatry.
[59] B. Moghaddam,et al. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. , 1998, Science.
[60] Vaughan J. Carr,et al. Systematic meta-review and quality assessment of the structural brain alterations in schizophrenia , 2012, Neuroscience & Biobehavioral Reviews.
[61] Philip D. Harvey,et al. Neuropsychological impairments in schizophrenia: Integration of performance-based and brain imaging findings. , 2007, Psychological bulletin.
[62] Tamara Hershey,et al. Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis , 1999, Neuropsychopharmacology.
[63] Thomas R Insel,et al. Toward new approaches to psychotic disorders: the NIMH Research Domain Criteria project. , 2010, Schizophrenia bulletin.